Dr Michael J. Miller joins Spore.Bio as VP of Scientific and Regulatory Affairs

Spore.Bio has appointed Dr Michael J. Miller (pictured above right) as its VP of Scientific and Regulatory Affairs as it seeks to embed rapid, modern microbiology in pharma manufacturing and other highly regulated industries.

An internationally recognised expert in rapid microbiological methods and contamination control, Dr Miller has nearly 40 years of experience in pharmaceutical microbiology, contamination control and the validation of rapid microbiological methods.

During that time he has held senior and executive roles in microbiology at Johnson & Johnson, Lilly and Bausch & Lomb.

“Spore.Bio is tackling a problem I’ve spent my entire career thinking about: how to make microbiology faster, more reliable, and more actionable for manufacturers,” he said.

“The combination of AI, biophotonics and microbiology Spore.Bio is building has the potential to redefine what ‘rapid methods’ mean. I’m excited to work with a firm that continues to set the standard for what a scientifically robust, validated and regulated platform can bring to users across pharma and beyond.”

In addition to advising the USP Microbiology Expert Committee, Dr Miller has authored more than 100 technical publications and presentations and is the chairperson for the revision of PDA Technical Report No. 33 – created to establish industry-wide criteria on what constitutes an acceptable alternative or rapid microbiology test.

Spore.Bio’s CEO Amine Raji (pictured above left) said: “Bringing the biggest key opinion leader of our field into Spore.Bio is a strong signal of where we’re headed as a company. His decades of experience in rapid methods, contamination control and regulatory strategy give us exactly the kind of scientific and regulatory backbone we need as we scale.”

Paris-headquartered Spore.Bio was founded in 2023 by Amine Raji, Maxime Mistretta (CTO) and Mohamed Tazi (COO) and, with its reagent free, AI driven microbiology platform for real time contamination monitoring, aims to disrupt microbiology testing technology.